For Immediate Release:
Contact: Janice Ohta
Athens, Georgia, September 20, 2016 – Abeome Corporation announced today that it has received notification from the National Institute of Health – National Heart, Blood and Lung Institute of an award granting $1,482,472 over two years for the further development of proprietary monoclonal antibodies in Abeome’s portfolio.
The grant, entitled “Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires,” is an SBIR Phase 2 award following a successful Phase 1 project in which Abeome’s proprietary AbeoMouseTM technology was used to discover novel functional antibodies directed to PCSK9. These antibodies have subsequently been shown to bind the PCSK9 protein at an epitope that is unique from those of other patented antibodies.
“We are very pleased that the National Heart, Lung and Blood Institute (NHLBI) recognizes the power of our proprietary antibody discovery platform, AbeoMouseTM for the rapid discovery of monoclonal antibodies. In addition to the anti-PCSK9 monoclonal antibodies our technology has successfully been used to identify high affinity functional antibodies to a wide array of other valuable targets,” stated Dr. Richard A. Shimkets, President and CEO of Abeome Corporation.
About the Grant: The grant provides funding for humanization and preclinical testing of the novel anti-PCSK9 monoclonal antibodies that neutralize PCSK9 function at high affinity, while also possessing other drug-like properties.
About AbeoMouse™: Abeome’s transgenic AbeoMouseTM platform enables the selection of desirable functional antibodies directly from the immune system of an immunized mouse. Traditional technology typically requires the screening of thousands of antibodies to find a few with drug-like properties. The direct probing of AbeoMouseTM antibody producing B-cells following immunization rapidly reveals single B-cells producing high affinity antibodies that either block or agonize the function of the target immunogens.
About Hypercholesterolemia: Elevated LDL cholesterol is one of the three main risk factors for heart disease, and over 14% of Americans suffer from high cholesterol. Over 200 million Americans take statins daily for the reduction of cholesterol, but statins are now known to contribute to the risk of developing diabetes, in addition to side effects such as memory loss and muscle damage. Current clinical trial findings suggest that suppression of PSCK9 function may be a safer and more effective way of reducing serum cholesterol.
About Abeome: Abeome is a privately held preclinical stage antibody discovery company with a pipeline of novel monoclonal antibody therapeutic candidates. Abeome’s objective is to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales. For more information, please visit www.abeomecorp.com
For more information, contact Janice Ohta (706)542-7889 Janice.email@example.com